Complete Mesocolic Excision in Comparison With Conventional Surgery for the Right Colon Cancer
Launched by UNIVERSITY OF TURIN, ITALY · Apr 28, 2021
Trial Information
Current as of July 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a type of surgery called Complete Mesocolic Excision (CME) to see how it compares to conventional surgery for patients with cancer in the right side of the colon. The goal is to find out if CME can improve outcomes for those needing surgery for this type of cancer. The trial is currently recruiting participants, specifically adults aged 65 to 85 who have a confirmed diagnosis of right colon cancer that has not spread to other parts of the body.
To be eligible for this trial, participants need to be in good overall health (graded I-III by the American Society of Anesthesiologists) and must provide informed consent. Certain individuals, such as those over 85 years old, those with obesity (BMI over 30), or those with other specific medical conditions, may not qualify. If you join the study, you will undergo either the CME procedure or the standard surgery and will be monitored closely to understand the effects of each method. This trial could help improve treatment options for future patients with similar conditions.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • American Society of Anesthesiologists(ASA) grade I-III.
- • Right colon cancer (\*The right-sided location of the cancer is defined as the location from the caecum up to the proximal third of the transverse colon), preoperative assessment of tumor stage T2-T4a, any N or T any N+ according to the National Comprehensive Cancer Network(NCCN) clinical practice guidelines in oncology: colon cancer version 2.2015); no distant metastasis.
- • Informed consent
- Exclusion Criteria:
- • Age \> 85 years old.
- • T1, N0
- • T4b, any N
- • BMI \> 30.
- • Metastatic disease (Abdominal and chest CT scan will be mandatory to exclude distant metastasis.)
- • American Society of Anesthesiologists(ASA) grade IV.
- • History of cancer in recent 5 years.
- • Need for Emergency surgery.
- • Infectious disease requiring treatment.
- • Pregnancy.
- • Use of systemic steroids.
- • No history of familial adenomatous polyposis, ulcerative colitis or Crohn's disease.
About University Of Turin, Italy
The University of Turin, located in Italy, is a prestigious academic institution renowned for its commitment to research and innovation in the medical field. As a clinical trial sponsor, the university leverages its extensive expertise and resources to advance scientific knowledge and improve patient outcomes. Collaborating with a network of healthcare professionals and researchers, the University of Turin conducts rigorous clinical trials that adhere to the highest ethical and regulatory standards. Its focus on translational research ensures that findings contribute to the development of effective therapies and healthcare solutions, enhancing the overall well-being of diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Milano, , Italy
Rome, , Italy
Genova, , Italy
Rome, , Italy
Grosseto, Arezzo, Italy
Sesto San Giovanni, Milano, Italy
La Spezia, Spezia, Italy
Candiolo, Torino, Italy
Pinerolo, Torino, Italy
Bologna, , Italy
Ferrara, , Italy
Messina, , Italy
Napoli, , Italy
Torino, , Italy
Patients applied
Trial Officials
Maurizio Degiuli, Professor
Principal Investigator
University of Turin, Department of Oncology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials